Search results for Ganitumab ELISA Kit
Ganitumab ELISA Kit, ProteoGenix, KPTX160
Description of Ganitumab ELISA Kit Ganitumab ELISA Kit: Structure, Activity, and Application Ganitumab ELISA Kit: Structure, Activity, and Application Introduction Ganitumab is a human monoclonal antibody that specifically targets the insulin-like growth factor-1 receptor (IGF-1R). It has shown promising results in clinical trials as a potential therapeutic agent for various types of cancer. The Ganitumab ELISA Kit is a valuable tool for researchers to measure the levels of Ganitumab in biological samples, providing insights into its structure, activity, and potential applications. Structure of Ganitumab Ganitumab is a fully human IgG1 monoclonal antibody with a molecular weight of approximately 150 kDa. It is composed of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region of Ganitumab binds to the extracellular domain of IGF-1R, while the constant region mediates its effector functions. The crystal structure of Ganitumab has been determined, revealing its binding mechanism to IGF-1R. The antibody binds to the ligand-binding site of the receptor, blocking the interaction between IGF-1 and IGF-1R. This leads to inhibition of downstream signaling pathways, ultimately resulting in inhibition of cell growth and survival in cancer cells. Activity of Ganitumab The primary activity of Ganitumab is its ability to specifically bind to IGF-1R and inhibit its activity. This results in decreased activation of downstream signaling pathways, such as the PI3K/Akt and MAPK pathways, which are crucial for cell growth and survival. Inhibition of these pathways leads to decreased proliferation and increased apoptosis in cancer cells. In addition, Ganitumab has also been shown to enhance the activity of other cancer treatments, such as chemotherapy and radiotherapy. This is due to its ability to sensitize cancer cells to these treatments, making them more susceptible to their effects. Application of Ganitumab ELISA Kit The Ganitumab ELISA Kit is a valuable tool for researchers to measure the levels of Ganitumab in biological samples. This can provide insights into the pharmacokinetics and pharmacodynamics of Ganitumab, as well as its potential efficacy and safety in clinical settings. The ELISA (enzyme-linked immunosorbent assay) is a commonly used technique for quantitative measurement of specific proteins in biological samples. The Ganitumab ELISA Kit utilizes a sandwich ELISA format, where the antibody is immobilized on a solid support and used to capture Ganitumab from the sample. A detection antibody labeled with an enzyme is then added, followed by a substrate that produces a colorimetric or fluorescent signal. The intensity of the signal is directly proportional to the amount of Ganitumab present in the sample. The Ganitumab ELISA Kit has been validated for use in various biological samples, including serum, plasma, and cell culture supernatants. It has a high sensitivity and specificity, making it a reliable tool for quantification of Ganitumab levels. This can aid in the development of dosing regimens and monitoring of treatment response in clinical trials. Conclusion The Ganitumab ELISA Kit is an essential tool for researchers studying the structure, activity, and potential applications of this promising therapeutic antibody. It provides a reliable and sensitive method for quantification of Ganitumab levels in biological samples, aiding in the understanding of its pharmacokinetics and pharmacodynamics. With ongoing clinical trials and potential future approvals, the Ganitumab ELISA Kit will continue to play a crucial role in the development and use of this therapeutic antibody.
Host
Reactivity
Applications
Conjugation
Ganitumab ELISA Kit, Abbexa, abx395049
Ganitumab ELISA Kit is a quantitative ELISA kit for detection of Ganitumab.Ganitumab (AMG-479) is a mAb against IGF-IR which also inhibits binding of both IGF-1 and IGF-2 ligands to IGF-IR. The therapeutic value of AMG-479 was evaluated in several preclinical settings including androgen-dependent prostate cancer, and combined with androgen-deprivation therapy. Ganitumab was found to be most potent against VCaP xenografts when it was used in combination with complete androgen-deprivation therapy. After 4 weeks of treatment, tumor volume was reduced by 72% and growth suppression was maintained over 16 weeks of treatment. These findings suggested that the use of ganitumab in conjunction with androgen-deprivation therapy may be beneficial in the treatment of prostate cancer.
Host
Reactivity
Human
Applications
ELISA
Conjugation
Please provide the required information below so that we can quickly source your products.